Ignite Creation Date:
2024-05-06 @ 6:50 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05808192
Status:
COMPLETED
Last Update Posted:
2023-04-11
First Post:
2023-03-29
Brief Title:
De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal
Sponsor:
University of Rome Tor Vergata
Organization:
University of Rome Tor Vergata
Study Overview
Official Title:
De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal
Status:
COMPLETED
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate de novo onset of metabolic syndrome NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy tolerant and in those taking immunosuppressive therapy non-tolerant
Detailed Description:
A retrospective single-center study was conducted aiming to define the incidence of de novo Metabolic Syndrome MS in patients who withdraw Immunosoppression IS drugs after Liver Transplant Tolerant-group compared to these who couldnt wean IS drugsnon-TOL-group
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None